Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up0.55% Nasdaq Up0.29%

PDL BioPharma, Inc. (PDLI)

8.17 0.04(0.49%) Apr 15, 4:00PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
PDL BioPharma, Inc.
932 Southwood Boulevard
Incline Village, NV 89451
United States - Map
Phone: 775-832-8500
Fax: 775-832-8501

Index Membership:N/A
Full Time Employees:10

Business Summary 

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on PDL BioPharma, Inc.

Corporate Governance 
PDL BioPharma, Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 3. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 7; Compensation: 2.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. John P. McLaughlin J.D., 62
Chief Exec. Officer, Pres, Director and Member of Litigation Committee
Mr. Christopher L. Stone J.D., 50
VP, Gen. Counsel and Sec.
Mr. Danny J. Hart Jr., J.D., 38
Deputy Gen. Counsel and Assistant Sec.
Mr. Peter S. Garcia , 52
Chief Financial Officer and VP
Mr. David Montez CPA,
Chief Accounting Officer and Controller
Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders